Ta strona używa pliki cookies, w celu polepszenia użyteczności i funkcjonalności oraz w celach statystycznych. Dowiedz się więcej w Polityce prywatności.
Korzystając ze strony wyrażasz zgodę na używanie plików cookies, zgodnie z aktualnymi ustawieniami przeglądarki.
Akceptuję wykorzystanie plików cookies
Advances in Psychiatry and Neurology
eISSN: 2720-5371
ISSN: 1230-2813
Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii
Current issue Archive Manuscripts accepted About the journal Scientific board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2025
vol. 34
 
Share:
Share:
abstract:
Review article

Intravenous tissue plasminogen activator in functional stroke mimics

Magdalena M. Kowalska
1
,
Małgorzata M. Michałowska
1
,
Marta M. Leńska-Mieciek
1

  1. Department of Neurology and Epileptology, Centre of Postgraduate Medical Education, Orłowski Hospital, Warsaw, Poland
Adv Psychiatry Neurol 2025; 34 (1): 33-43
Online publish date: 2025/04/30
View full text Get citation
 
PlumX metrics:
Purpose:
Time pressure in the treatment of acute ischemic stroke patients generates difficult decisions for neurologists, sometimes resulting in stroke mimic patients receiving intravenous thrombolytic therapy. Proper diagnosis and appropriate treatment for these patients are crucial, yet incredibly challenging in cases of functional stroke mimics (FSM).

Views:
Functional neurological disorders, including FSM, are increasingly diagnosed. However, their pathophysiology and underlying mechanisms are poorly understood, even though the diagnostic criteria for diagnosing FSM exist, and various clinical indicators support them. Functional neurological symptoms often result in serious disability for patients but the effective treatment is unknown. Neurologists need to examine the symptoms and the key clinical findings to distinguish between FSM and stroke. The intravenous thrombolytic therapy appears safe for FSM, but the potential harm of thrombolysis should be a concern. FSM- diagnosed patients require long-term treatment, starting with open and clear communication about their condition and followed by psychoeducation and physiotherapy.

Conclusions:
FSM should be diagnosed using the diagnostic criteria. Electronic health information exchange among healthcare providers is necessary to avoid unnecessary thrombolytic treatments in this group of patients.

keywords:

functional stroke mimics, functional neurological disorders, thrombolytic treatment, ischaemic stroke, functional weakness

Quick links
© 2025 Termedia Sp. z o.o.
Developed by Bentus.